There are animal studies that not only show improvement in their cognitive functions but also improves sleep boost memory, lower anxiety and depression levels and reduces withdrawal symptoms. People who have tried nootropic Fasoracetam also claim to have all these improvements. And there are more experiments being tried with this newly discovered drug as more and more people get newer positive symptoms. This had also lead to the US Food and Drug Administrations or the US FDA permitting it in human trials as early as 2015. It cites many effective positive findings in the human body.
It is now undergoing more clinical tests for effectiveness against other mental illnesses. This is how it was discovered and how it came to be in the market:
- Fasoracetam was first discovered by Japanese scientists from a pharmaceutical company called Nippon Shinyaku. They tested it for effectiveness against vascular dementia and brought it all the way up to phase 3 clinical testing. But then ended up abandoning it for lack of effectiveness.
- Then a scientist of the name HakonHakonarson leads his team to study nootropic Fasoracetam at Children’s Hospital of Philadelphia. They studied its potential use to cure ADHD or Attention Deficit Hyperactivity Disorder.
- After discovering its efficiency for ADHD, Hakonarson decided to start a company to try to get nootropic Fasoracetam into the medical market. It was called neuroFix and was a US-based company. After establishing neuroFix, they managed to buy all the clinical data from Nippon Shinyaku.
- Another company called Medgenics acquired neuroFix and changed its name shortly to Aevi Genomic. They then started clinical trials on adolescents who have ADHD with a mGluR mutation. Nootropic Fasoracetam was shown to be effective in treatment for people who have ADHD with specific mGluR mutations. These represent 10% of all ADHD cases, making it a great discovery. However, it was shown to be ineffective for other types of ADHD.
Nootropic pramiracetam is a newly discovered drug that has been shown to improve cognitive functions in mice. It was initially tested for effectiveness against vascular dementia. While it may not have been effective against vascular dementia, it was very useful against ADHD with a mGluR mutation. It has now been released as a prescription drug in Australia. It can be orally consumed by people to cure 10% of all ADHD cases or all ADHD cases with a mGluR mutation. One can get this drug with a prescription, as it is currently a prescription-only drug in Australia.
In the USA, the FDA has not yet cleared it as a drug for human use despite its vast positive effects on the human body. It is undergoing more experiments to find out more about its effects on human bodies and its various positive effects. It is being considered as a cure for patients who have ADHD with a mGluR mutation.